CRSP Crispr Therapeutics AG
Company Analysis
Latest News
🟢 Crispr Therapeutics AG extends move to 5.3% up
CRSP is trading at $54.77, up 5.3% versus the comparison close of $52.02 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Crispr Therapeutics AG is trading 4.0% up today amid dip-buying interest
Crispr Therapeutics AG is trading 4.0% up at $54.11 today amid dip-buying interest following recent volatility. • The stock’s gain follows a period of price...
🟢 Crispr Therapeutics AG is trading 6.1% up today as broad market rally and pipeline optimism fuel rebound
Crispr Therapeutics AG is trading 6.1% up at $52.84 as the stock rebounds from recent biotech sector weakness amid a broader market rally and positive pipeline...
🟢 Crispr Therapeutics AG is trading 4.5% up today amid broader market rebound
Crispr Therapeutics AG is trading at $51.65 (+4.5%) in pre-market as the stock rebounds from yesterday's decline amid improved risk sentiment for biotech and...
🔴 Crispr Therapeutics AG is trading 10.0% down today as strong jobs data triggers growth selloff
Crispr Therapeutics AG is trading at $51.24 (10.0% down) as a stronger-than-expected U.S. jobs report pressures rate-sensitive growth stocks and prompts...
🔴 Crispr Therapeutics AG is trading 4.71% down today amid a broad tech-led selloff and profit-taking
Crispr Therapeutics AG is trading at $54.27 (-4.71%) today, giving back a portion of its June 4 rally during a wider market retreat. • The decline aligns with...
CRSP Surges 12% on CEO's Bullish Conference Talk — But Can a $43 Million Therapy Justify $4.7 Billion in Market Value?
Shares of Crispr Therapeutics vaulted 12.2% to $58.45 on June 4 after CEO Samarth Kulkarni delivered an upbeat fireside chat at the Jefferies Global Healthcare...
🟢 Crispr Therapeutics AG is trading 12.2% up today after CEO highlights strong CASGEVY outlook
Crispr Therapeutics AG is trading 12.2% up at $58.45 after CEO Sam Kulkarni delivered an upbeat presentation at the Jefferies Global Healthcare Conference. •...
🟢 Crispr Therapeutics AG soars 13.2% after CEO highlights promising pipeline at investor conference
Crispr Therapeutics AG is trading up 13.2% today at $58.94 following an optimistic presentation by CEO Sam Kulkarni at the Jefferies Global Healthcare...
🔴 Crispr Therapeutics AG is trading 4% down despite potentially positive FDA guidance for the gene therapy sector
Crispr Therapeutics AG is trading 4% down at $52.01, a move that comes amid mixed signals for the gene-editing sector. While the stock appears to be undergoing...